c19early.org COVID-19 treatment researchCOVID-19 treatments

iC1e/K for COVID-19: real-time analysis

c19early.org
iC1e/K for COVID-19
1 study with 20 patients
Serious outcome risk
iC1e/K
Control
No significant improvements are seen in meta-analysis to date.
COVID-19 iC1e/K studies · November 2026
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)0%
Mortality (1)0%
RCTs (1)0%
Late (1)0%
00.511.5+
← iC1e/K
reduces riskIncreased
risk →
Feb 16
2021
 Mansour et al., Viruses, doi:10.3390/v13020309 Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19
no change in mortality (p=1) and 35% lower hospital discharge (p=0.36). RCT 30 severe COVID-19 patients showing no significant difference in mortality or hospitalization time with kinin-kallikrein system inhibitors icatibant or iC1e/K. While there was no impact on mortality or hospitalization time, both treat..